Brenda Tromp

1.3k citations

11 papers · 263 indexed · h-index 5

Immunology
Oncology
- Peptidase Inhibition and Analysis 4
Genetics
- Chronic Lymphocytic Leukemia Research 4
Hematology
- Multiple Myeloma Research and Treatments 4
Cancer Research
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 3
Molecular Biology
- Protein Degradation and Inhibitors 3
- Amyloidosis: Diagnosis, Treatment, Outcomes 2
- Glycosylation and Glycoproteins Research 1
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 2

Co-authors: Shahneen Sandhu Thomas A. Puchalski Amita Patnaik Johann S. de Bono Birge Berns Anthony W. Tolcher David Olmos Christina Messiou
Cited by: Immunology Oncology Genetics
Journals: Journal of Clinical Oncology (4 papers)Blood (4 papers)Cancer Chemotherapy and Pharmacology (1 paper)
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Brenda Tromp

11 papers receiving 259 citations

Peers

Countries citing papers authored by Brenda Tromp

Since Specialization

Citations

This map shows the geographic impact of Brenda Tromp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda Tromp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda Tromp more than expected).

Fields of papers citing papers by Brenda Tromp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brenda Tromp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda Tromp. The network helps show where Brenda Tromp may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Brenda Tromp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brenda Tromp Line = papers co-authored together Brenda Tromp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work
1	Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study Leukemia & lymphoma ·Hareth Nahi,Saad Z. Usmani,María‐Victoria Mateos,Niels W.C.J. van de Donk,Albert Oriol,Torben Plesner,Nibedita Bandyopadhyay,Peter Hellemans,Brenda Tromp,Ivo Nnane,Donna Zemlickis,Ajai Chari,Philippe Moreau	2023	1
2	Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma Journal of Oncology Pharmacy Practice ·María‐Victoria Mateos,Sophie Rigaudeau,Supratik Basu,Ivan Špıčka,Rik Schots,Tomasz Wróbel,Gordon Cook,Meral Beksaç,Katharine S. Gries,Anupa Kudva,Brenda Tromp,Rian Van Rampelbergh,Huiling Pei,Susan Wróblewski,Robin Carson,Maria Delioukina,Darrell White	2022	10
3	Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study Blood ·Hareth Nahi,Saad Z. Usmani,María‐Victoria Mateos,Niels W.C.J. van de Donk,Philippe Moreau,Albert Oriol,Torben Plesner,Nibedita Bandyopadhyay,Peter Hellemans,Brenda Tromp,Ivo Nnane,Donna Zemlickis,日野原敦子,Ajai Chari	2021	2
4	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda Blood ·Ashutosh Wechalekar,Giovanni Palladini,Giampaolo Merlini,Raymond L. Comenzo,Arnaud Jaccard,NamPhuong Tran,Huiling Pei,Sandra Y. Vasey,Brenda Tromp,Brendan M. Weiss,Jessica Vermeulen,Efstathios Kastritis	2020	5
5	Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study. Journal of Clinical Oncology ·Hareth Nahi,Saad Z. Usmani,María‐Victoria Mateos,Niels W.C.J. van de Donk,Philippe Moreau,Albert Oriol,Torben Plesner,Shiyi Yang,Peter Hellemans,Brenda Tromp,Man Luo,Donna Zemlickis,日野原敦子,Ajai Chari	2020	1
6	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda Blood ·Monique C. Minnema,Angela Dispenzieri,Giampaolo Merlini,Raymond L. Comenzo,Efstathios Kastritis,Ashutosh Wechalekar,Martha Grogan,Ronald Witteles,Frederick L. Ruberg,Matthew J. Maurer,NamPhuong Tran,Xiang Qin,Sandra Y. Vasey,Brenda Tromp,Brendan M. Weiss,Jessica Vermeulen,Arnaud Jaccard	2020	4
7	A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Shahneen Sandhu,K. Papadopoulos,Peter C.C. Fong,Amita Patnaik,Christina Messiou,David Olmos,George Wang,Brenda Tromp,Thomas A. Puchalski,Frances R. Balkwill,Birge Berns,Shobha Seetharam,Johann S. de Bono,Anthony W. Tolcher	2013	228
8	An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease Blood ·Frits van Rhee,Corey Casper,Peter M. Voorhees,Luis Fayad,Helgi van de Velde,Jessica Vermeulen,Xiang Qin,Ming Qi,Brenda Tromp,Razelle Kurzrock	2013	7
9	Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors. Journal of Clinical Oncology ·Eric Angevin,Élena Elez,Steven J. Cohen,Jean‐Luc Van Laethem,Christian H. Ottensmeier,Florence Joly,Isabelle Ray‐Coquard,José A. López-Martín,Luc Dirix,Jean‐Pascal Machiels,Sally Clive,Neil Steven,Manjula Reddy,Brett M. Hall,Thomas A. Puchalski,Rajesh Bandekar,Helgi van de Velde,Brenda Tromp,Jessica Vermeulen,Razelle Kurzrock	2012	2
10	Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Martin Förster,Amita Patnaik,Shahneen Sandhu,K. Papadopoulos,Brenda Tromp,Christina Messiou,Frances R. Balkwill,Birge Berns,Johann S. de Bono,A. W. Tolcher	2010	1
11	First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors Journal of Clinical Oncology ·Shahneen Sandhu,Peter C.C. Fong,Sophia Frentzas,Amita Patnaik,K. Papadopoulos,Brenda Tromp,Thomas A. Puchalski,Birge Berns,Anthony W. Tolcher,Johann S. de Bono	2009	2

About Brenda Tromp

Brenda Tromp is a scholar working on Genetics, Hematology and Oncology, having authored 11 papers that have together received 263 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (4 papers), Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Protein Degradation and Inhibitors (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (2 papers) and Glycosylation and Glycoproteins Research (1 paper). The work is most often cited by research in Immunology (170 citations), Oncology (149 citations) and Genetics (21 citations). Brenda Tromp has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Shahneen Sandhu, Thomas A. Puchalski, Amita Patnaik, Johann S. de Bono, Birge Berns, Anthony W. Tolcher, David Olmos, Christina Messiou, George Wang and Frances R. Balkwill. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Chemotherapy and Pharmacology, Leukemia & lymphoma and Journal of Oncology Pharmacy Practice.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact